Skip to main content
SpringerLink
Log in

Insulin Use

  • Chapter
  • First Online:
Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome

Part of the book series: Current Clinical Practice ((CCP))

  • 3249 Accesses

Abstract

Several clinical trials covering thousands of patient cohorts have clearly demonstrated the correlation between the long-term macro and microvascular complications of diabetes and poorly controlled blood glucose with the subsequent benefits of tighter glycemic control. This data has made us all much more aware that insulin, used even in the early stages of diabetes, to insure proper control, can be invaluable in reducing mortality and morbidity. In fact, earlier insulin use reduces glucose toxicity, allows endogenous insulin to function more efficiently and reduces the strain on the deteriorating beta cell [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bastyr EJ, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering A1C. Diabetes Care. 2000;23:1236–1241.

    Article  PubMed  CAS  Google Scholar 

  2. Mudulair S, Edelman SV. Insulin therapy in type-2 diabetes. Endocrinol Metab Clin North Am. 2001;30:935–982.

    Article  Google Scholar 

  3. Nathan DM, Buse JB, Davidson MB. American Diabestes Association: European Association for Study of Diabetes. Medical management of hyperglycemia in type-2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29(8):1963–1972.

    Google Scholar 

  4. Mayfield J, White RD. Insulin therapy for type-2 diabetes: rescue, augmentation and replacement of beta cell function. Am Fam Physician. 2004;70:489–500.

    PubMed  Google Scholar 

  5. Burge MR, Schade DS. Insulins. Endocrinol Metab Clin North Am. 1997;26:575–598.

    Article  PubMed  CAS  Google Scholar 

  6. Kudlacek S, et al. The effect of insulin treatment on HbA1C, body weight and lipids in type 2 diabetic patients with secondary failure to sulfonylureas. Horm Metab Res. 1992;24:478–483.

    Article  PubMed  CAS  Google Scholar 

  7. American Diabetes Assoicaiton. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25(suppl 1):S33–S49.

    Google Scholar 

  8. Hermann LS. Optimizing therapy for insulin treated type 2 diabetes mellitus. Drugs Aging. 2000;17:283–294.

    Article  PubMed  CAS  Google Scholar 

  9. United Kingdom Prospective Diabetes Study group. (1998). A randomized trial of efficacy of addition of metformin to sulfonylurea. Diabetes Care. 21:87–92.

    Article  Google Scholar 

  10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.

    Article  Google Scholar 

  11. Van den Berghe G, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2002;346:1587–1588.

    Google Scholar 

  12. Bastyr EJ, Stuart CA, Brodows RG. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowereing A1C. Diabetes Care. 2000;23:1236–1241.

    Article  PubMed  CAS  Google Scholar 

  13. DeVeciana M, et al. Targeting postprandial glucose in gestational diabetics improves HbA1C outcomes over 6 weeks. N Engl J Med. 1995;333:1239.

    Google Scholar 

  14. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 2001;30:935–982.

    Article  PubMed  CAS  Google Scholar 

  15. Rosenstock J, et al. Basal insulin therapy in type 2 diabetes: 28 week comparison of insulin glargine and NPH insulin. Duiabetes Care. 2001;24:631–636.

    Article  CAS  Google Scholar 

  16. Unger J. Targeting glycemic controlin the primary care setting. Female Patient. 2003;28:12–16.

    Google Scholar 

  17. Heller S, Kurtzhals P, et al. Insulin aspart: promising early results borne out in clinical practice. Expert Opin Pharmacother. 2002;3:183–195.

    Article  PubMed  CAS  Google Scholar 

  18. Antsiferov M, et al. Within patient variability in postprandial glucose excursion with lispro insulin analog compared with regular insulin. Diabetologia. 1995;38(suppl 1):A190.

    Google Scholar 

  19. Home PD, et al. Insulin Aspart Study Group. Improved glycemic control with insulin aspart: a multicenter randomized double blind crossover trial in type 1 diabetic patients. Diabetes Care. 1998;21:1904–1909.

    Google Scholar 

  20. Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins. Am J Med. 2008;121:S9–S19.

    Article  PubMed  CAS  Google Scholar 

  21. Holleman F, et al. Comparison of Lispro and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care. 1996;19:1426–1429.

    Article  PubMed  CAS  Google Scholar 

  22. Schreiber SA, Haak T. Insulin glargine benefits patients with type-2 diabetes inadequately controlled on oral antidiabetic treatment. Diabetes Obes Metab. 2007;9:31–38.

    Article  PubMed  CAS  Google Scholar 

  23. Raskin P, et al. A 16 week comparison of the novel analog insulin glargine and NPH insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23:1666–1671.

    Article  PubMed  CAS  Google Scholar 

  24. Heinemann L, Linkeschova R, Rave K. Time-action profile of the long acting insulin analog insulin glargine. Diabetes Care. 2000;23:644–649.

    Article  PubMed  CAS  Google Scholar 

  25. Lepore M, et al. Pharmacokinetics and parmacodynamics of subcutaneous injection of long acting human insulin glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;23:1137–1142.

    Google Scholar 

  26. Rosenstock J, Schwartz SL, Clark CM. Basal Insulin therapy in type-2 diabetes: 28 week comparison of insulin glargine and NPH insulin. Diabetes Care. 2001;24:631–636.

    Article  PubMed  CAS  Google Scholar 

  27. Rosenstock J. Treatment of target study:glargine or NPH in insulin naïve patients with type-2 diabetes on oral agents. Diabetes. 2001;50(suppl 2):A129. Abstract 520-P.

    Google Scholar 

  28. Kelly JI, et al. Rapid decrease in clinically significant hypoglycemia with insulin glargine. Diabetes. 2002;51(suppl 2):A123.

    Google Scholar 

  29. Jonasson JM, Ljung R, Talbäck M. European Association for the Study of Diabetes. Insulin glargine and malignancy. Diabetologia. 2009:1418–1440.

    Google Scholar 

  30. Klein O, Lynge J, Endahl L. Insulin detemir and insulin glargine: similar time action profiles in subjects with type-2 diabetes. Diabetes. 2006;55(9 suppl):325.

    Google Scholar 

  31. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernhaner G. A randomized 52 week treat to target trial comparing insulin detimir with insulin glargine when administered as add on to glucose lowering drugs in insulin naïve people with type-2 diabetes. Diabetologia. 2008;51:408–416.

    Article  PubMed  CAS  Google Scholar 

  32. Meneghini L, Koenen C, Weng W, Selam JL. The usage fo a simplified self titration dosing guideline for insulin detimir in patients with type-2 diabetes – the PREDICTIVE study. Diabetes Obes Metab. 2007;357:1716–1730.

    Google Scholar 

  33. Luddeke HJ, Philotheou A, Horn-rosenberg K. PREDICTIVE: a global, prospective observational study to evaluate insulin detimir treatment in type1 and type 2 daibetes. Diabet Med. 2006;23(suppl 4):139.

    Google Scholar 

  34. Nathan DM, Buse JB, Davidson MD. Medical management of hyperglycemia in type 2 diabetes. Diabetes Care. 2009;32(1):193–203.

    Article  PubMed  CAS  Google Scholar 

  35. Kovisto VA, Tuominen JA, et al. Lispro mix insulin as pre-meal therapy in type 2 diabetic patiens. Diabetes Care. 1999;22:459–462.

    Article  Google Scholar 

  36. Malone JK, et al. Improved postprandial glycemic control with Humalog Mix 75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther. 2000;22:222–230.

    Article  PubMed  CAS  Google Scholar 

  37. MassiBenedetti M, Humburg E, Dressler A, Ziemen M. A one year, randomized, muldticentre trial comparing insulin glragine with NPH insulin in combination with oral agents in patients with type-2 diabetes. Horm Metab Res. 2003;35:189–196.

    Article  PubMed  CAS  Google Scholar 

  38. Yki-Jarvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J. Effect of obesity on the response to insulin therapy in non-insulin dependent diabetes mellitus – The FINMIS study. J Clin Endocr Metab. 1997;82(12):4037–4043.

    Article  PubMed  CAS  Google Scholar 

  39. Riddle MC, Rosenstock J, Gerich J. The Treat to Target trial. Diabetes Care. 2003;26:3080–3086.

    Article  PubMed  CAS  Google Scholar 

  40. Cefalu WTR. Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. Ann Med. 2001;33:579–586.

    PubMed  CAS  Google Scholar 

  41. Stewart KM. Insulin delivery devices. J Pharm Pract. 2004;17:20–28.

    Article  Google Scholar 

  42. Wilson M, Weintreb J, Hoo GW. Intensive insulin therapy in critical care. Diabetes Care. 2007;30:1005–1011.

    Article  PubMed  CAS  Google Scholar 

  43. Cook CB, Boyle ME, Cisar NS. Use of continuous subcutaneous insulin infusion/insulin pump therapy in the hospital setting. Diabetes Educ. 2006;32:130. Diabetes Educ. 2005;31:849–857.

    Google Scholar 

  44. Palumbo P. The case for insulin treatment early in type 2 diabetes. Clev Clin J Med. 2004;71(5):385–386.

    Google Scholar 

  45. Owens DR, Zinman B, Insulins today and beyond. Lancet. 2004;71(5):385–386.

    Article  PubMed  CAS  Google Scholar 

Supplementary Readings

  • Boehm BO, et al. Premixed insulin aspart 30 vs. premixed human insulin 70/30 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med. 2002;19:393–399.

    Article  PubMed  CAS  Google Scholar 

  • Dornhorst A, Luddeke HJ, Sreenan S. Safety and efficacy of insulin detimirin clinical practice. Int J Clin Pract. 2007;61:523–528.

    Article  PubMed  CAS  Google Scholar 

  • Hermann L. Combination therapy with insulin and metformin (The Fin-Fat Study). Endocr Pract. 1998;4(6).

    Google Scholar 

  • Hirsch IB, et al. Role of insulin in management of surgical patients with diabetes mellitus. Diabetes Care. 1990;13:980–991.

    Article  PubMed  CAS  Google Scholar 

  • Home P, Kurtzhals P. Insulin detimir: from concept to clinical experience. Expert Opin pharmacother. 2006;7:325–343.

    Article  PubMed  CAS  Google Scholar 

  • Meneghini LF, Rosenberg KH, Loenen C. Insulin detimir improves glycemic control with less hypoglycemia and no weight gain in patients with type-2 diabetes. Diabetes Obes Metab. 2007;9:418–427.

    Article  PubMed  CAS  Google Scholar 

  • Ordoubadi FF, et al. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;96:1152–1156.

    Article  Google Scholar 

  • Raslova K, Bogoev M, Raz I. Insulin detemir and insulin aspart. Diabetes Res Clin Pract. 2004;66:193–201.

    Article  PubMed  CAS  Google Scholar 

  • Standl E. Insulin analogues-state of the art. Horm Res. 2002;57(suppl 1):4045.

    Google Scholar 

  • Van den Berghe G, Wouters P, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–1367.

    Article  PubMed  Google Scholar 

  • Queale WS, et al. Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med. 1997;157:545–552.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pennsylvania Health System Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA

    Ronald A. Codario MD, FACP (Clinical Instructor in Medicine)

Authors
  1. Ronald A. Codario MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Diplomate American Board of Internal Medicine

Diplomate American Board of Clinical Lipidology

Diplomate American Board of Vascular Medicine

Clinical Hypertension Specialist (American Society of Hypertension Certified)

Vascular Ultrasound (American Registry of Diagnostic Sonography Certified)

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Codario, R.A. (2011). Insulin Use. In: Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-441-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-441-8_7

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-440-1

  • Online ISBN: 978-1-60327-441-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation